NCT05753826View on ClinicalTrials.gov

Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.

PHASE2RecruitingINTERVENTIONAL

Enrollment

37

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions

Ovarian NeoplasmsOvarian Diseases

Interventions

DRUG

Adebrelimab

20mg/kg，D1，q3W

DRUG

Fuzuloparib

100 mg bid

Trial Locations (1)

Unknown

RECRUITING

Fujian Cancer Hospital, Fujian

All Listed Sponsors

lead

Fujian Cancer Hospital

OTHER_GOV